key: cord-0726064-zn28xy7a
authors: AbdulRahim, Nashila; McAdams, Meredith; Xu, Pin; Wojciechowski, David; Hoz, RicardoLa; Lu, Christopher; Vazquez, Miguel A.; Hedayati, S. Susan
title: Association of Inflammatory Biomarkers with Immunosuppression Management and Outcomes in Kidney Transplant Recipients with COVID-19
date: 2021-08-09
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2021.08.002
sha: 92a4db4a2c11d8023d7dbec27f0f32356919188d
doc_id: 726064
cord_uid: zn28xy7a

INTRODUCTION: Kidney transplant recipients with COVID-19 are at increased risk for adverse outcomes, such as Acute Kidney Injury (AKI), Intensive Care Unit (ICU) admission, and death. The association of inflammatory biomarkers with outcomes and impact of changes in immunosuppression on biomarker levels are unknown. METHODS: We investigated factors associated with a composite of AKI, ICU admission, or death, and whether immunosuppression changes correlated with changes in inflammatory biomarkers and outcomes in kidney transplant recipients with a positive SARS-CoV2 PCR. RESULTS: Of 59 patients, 50% had eGFR<60 mL/min/1.73 m(2). Patients who discontinued calcineurin-inhibitors (CNI) had higher peak hsCRP than those who maintained the same dose, median (IQR) 344 (145-374) vs. 41 (22-116) mg/L, p=0.03. 73% were hospitalized, 22% had ICU admissions, and 20% died. 56% had AKI, of which 35% required dialysis. All with AKI but without pulmonary manifestations recovered to 10% of baseline creatinine. Factors associated with the composite outcome were eGFR<60, OR (95% CI)=5.833 (1.880-18.099), p=0.002, hsCRP, OR=1.011 per unit increase (1.002-1.021), p=0.019, WBC, OR=1.173 per unit increase (1.006-1.368), p=0.041, and having CNI decreased or discontinued, OR=4.286 (1.353-13.572), p=0.013. eGFR<60, OR=11.176 (1.581-79.001), p=0.016, and peak hsCRP, OR =1.010 per unit increase (1.000-1.020), p=0.049 remained associated with the composite in the multivariable model. CONCLUSIONS: Kidney transplant recipients with COVID-19 have high rates of ICU admissions, AKI, and death. Those with eGFR<60 are at highest risk. CNI reduction is associated with higher inflammatory biomarkers, correlating with worse outcomes. More studies are needed to determine if this association should drive clinical management.

Comorbid conditions, such as hypertension, diabetes mellitus, and cardiovascular disease, increase the morbidity and mortality of COVID-19 in the general population. In addition to one or more of these, kidney transplant recipients also harbor a unique set of elements, such as exposure to induction therapies, duration of maintenance immunosuppression, and periods of immunosuppression augmentation, that may increase the risk of complications in the setting of COVID-19 infection. Furthermore, different classes of immunosuppression add a unique layer of complexity to a population already debilitated with concomitant medical conditions.

In COVID-19 infected kidney transplant recipients, safety and efficacy of potential therapeutics, acute kidney injury (AKI) incidence and rates of recovery, and cautious, but timesensitive, adjustments of immunosuppression are several areas worth investigation to guide clinical management. Although AKI is an important prognosticator of future chronic kidney disease (CKD), there is a paucity of data on rates of AKI in this setting. The existing data are variable, ranging from 20 to 50% in published cohorts [1] [2] [3] [4] [5] . AKI rates requiring renal replacement therapy (RRT) show less variability ranging from 11-23% 5-7 . However rates of renal recovery following AKI are not widely reported. In fact, the majority of published literature to date has been descriptive reports from transplant centers recounting experiences with COVID-19 in kidney transplant recipients, describing outcomes, and proposing a generalized immunosuppression management plan based on these experiences 1, [5] [6] [7] [8] [9] .

In kidney transplant recipients with COVID-19, the optimal immunosuppression management is unknown. For example, reduction may halt progression of severe respiratory illness but it may not ameliorate (and may cultivate) the cytokine storm phenomena and increase mortality risk. 10, 11 . Therapeutic strategies have intuitively employed immunosuppression reduction similar to that in other viral illnesses, specifically Cytomegalovirus (CMV) and polyomavirus 12, 13 . Lowering or cessation of antimetabolite has been the mainstay strategy in the majority of viremic states requiring hospitalization. Thus, it is no surprise that a comparable approach was employed by transplant nephrologists at the inception of the pandemic. However, these reports did not sufficiently examine independent risk factors associated with outcomes in kidney transplant recipients hospitalized with COVID-19, using well-controlled, multivariate models.

In addition, the independent role of inflammatory biomarkers in outcome prediction or the impact of changes in immunosuppressant regimen on the levels of these biomarkers in the setting of kidney transplantation and COVID-19 are still unclear. Few studies reported that plasma C-reactive protein (CRP) levels are elevated in patients with COVID-19 and may correlate with severity of disease and death 6, 14, 15 . An observational study from the French Registry of Solid Organ Transplant Recipients described that elevated CRP was associated with severe COVID-19 disease 5 , but did not explore association of CRP with outcomes such as AKI.

In addition, no studies have explored the association of changes in baseline immunosuppression regimen with changes in inflammatory biomarkers or effect on outcomes in kidney transplant patients.

Our study was, therefore, designed to address these knowledge gaps using the following aims: (1) investigate factors associated with a pre-specified outcome of AKI, intensive care unit (ICU) admission or death in kidney transplant patients with COVID-19 infection; (2) describe how immunosuppression regimen was modified and what COVID-19 treatments were delivered;

(3) whether changes made to immunosuppression regimen correlated with outcome measures and changes in markers of inflammation (4) describe time to recovery of AKI at 90 days after COVID-19 infection for those who experienced AKI.

This analysis used data from the Electronic Health Records (EHR) at the University of Texas Southwestern Medical Center (UTSW) outpatient clinics, William P. Clements University Hospital (CUH) and Parkland Health and Hospital System (PHHS) in Dallas, Texas. All kidney transplant recipients from CUH and PHHS with a positive SARS-CoV-2 PCR from 3/1/2020-10/1/2020 were included. Individuals with non-functioning kidney allografts were excluded. The study was approved by UTSW Institutional Review Board.

Demographic variables, past medical history, and medication data were collected at the time of positive SARS-CoV-2 PCR and throughout illness using the EHR. Laboratory variables, including inflammatory biomarkers if available, were also obtained. Any COVID-19 specific treatments utilized were evaluated, as well as any changes (discontinuation or dose increase or decrease) to the individuals' baseline immunosuppression regimen while infected with COVID-19. In order to determine differences due to illness severity, participants were grouped by presence or absence of pulmonary manifestations of COVID-19, defined as either requiring any form of supplemental oxygen, mechanical ventilation, or a pulmonary infiltrate noted on chest xray. To evaluate the differences due to kidney donor type, patients were grouped by either having a living or deceased donor.

Participants were followed prospectively for up to 90 days after the diagnosis of COVID-19. The pre-specified primary outcome was defined as a composite of AKI, admission to the ICU, or death. Pre-specified secondary outcomes included each component of the composite assessed separately. AKI was defined using Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines. The recovery of AKI, another pre-specified secondary outcome measure, was defined as a decrease in the serum creatinine to within 10% of the baseline serum creatinine value in 90 days after positive SARS-CoV-2 test. Patients who died or were initiated on maintenance dialysis were considered to have not recovered from AKI.

Baseline variables were reported using proportions for categorical variables, means ± standard deviation (SD) for continuous variables with a Gaussian distribution, and median (interquartile range (IQR)) for those with a non-Gaussian distribution. Univariate and multivariate logistic regression models were used to investigate the associations of clinical factors with the outcomes of AKI, ICU admission, or death taken as a composite. Odds ratio (OR) with 95% confidence intervals (CI) were reported. Variables that were significantly associated with the outcome measure in univariate models (p-value <0.1) were included in the multivariable model and the final model was selected using stepwise backward selection method, with an apriori retention p-value of <0.1. Variables tested included age, race, sex, presence of diabetes mellitus, baseline estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 , time since transplantation <1 year, maintenance immunosuppression with an anti-metabolite prior to COVID-19 positive test, insurance status (patients holding no insurance or Medicaid were combined into a group and patients holding Medicare or private medical insurance were combined into another group), high sensitivity C-reactive protein (hs-CRP), white blood cell count (WBC), calcineurin inhibitor (CNI) regimen change, and presence of pulmonary manifestations as described above. Covariates that were retained in the multivariable backward selection model were age, eGFR <60, peak HsCRP, peak WBC, decrease or discontinuation of CNI, and COVID pulmonary manifestations.

Adjustments to maintenance immunosuppression regimen, including changes in medications and dosing, were described after COVID-19 diagnosis. In addition, the proportion of patients receiving COVID-specific treatments such as high-dose steroids (IV hydrocortisone, dexamethasone or methylprednisolone), remdesivir, Interleukin-6 (IL-6) inhibitors, convalescent plasma, azithromycin, hydroxychloroquine, anticoagulation, supplemental oxygen, ICU, mechanical ventilation, and vasopressors was described.

The distribution of changes in inflammatory biomarkers (baseline, peak, and final hospitalization values) were described using box plot, medians, IQR, and the correlations with immunosuppression regimen modifications were investigated in two and three level comparisons. The two-level comparisons were between no changes in medication vs decreased or discontinued and nonparametric Mann Whitney U test was performed. The three level comparisons were no change in mediation vs decrease in medication vs discontinuation in medication and nonparametric ANOVA (Kruskal-Wallis test) followed by Dunn's test with p values adjusted with Holm's method at α = 0.05 was carried out. Sensitivity analyses were done including only patients who had their CNI or anti-metabolite changed prior to the biomarkers being collected.

A separate model was constructed to test the main effects of CNI (no change vs decreased or discontinued) and pulmonary manifestations (present vs absent), plus the interaction term of the two variables in the logistic regression model for the composite outcome.

A total of 59 patients with functioning kidney allografts who tested positive for SARS-CoV by PCR testing were included in the analysis. The clinical features, baseline characteristics, and laboratory values at the time of diagnosis are outlined in Table 1 Table 1) .

COVID-related treatments received by participants and outcomes are shown in Table 3 .

Treatments and outcomes based on allograft donor type are shown in Table 4 . There were 31 composite events, including 12 deaths (20.3%), 13 with ICU admissions (22.0%), and 29 experiencing AKI (55.8%) ( Table 3) . Overall, 43 of 59 (72.9%) patients required hospitalization and of those, 28 (65.1%) met criteria for AKI, and 10 of the 28 with AKI (34.5%) required RRT.

Of the total 29 patients with AKI, 10 died, one initiated maintenance hemodialysis, and one did not have a serum creatinine at 90-day follow-up. Therefore, follow-up serum creatinine values were available for 28 patients with AKI, and 13 (46.4%) recovered kidney function.

Those with pulmonary manifestations were more likely to be treated with high-dose steroids, remdesivir, anticoagulation, and vasopressors ( Table 3) . There was a trend towards a higher rate of AKI in those with pulmonary manifestations and those without, 63% vs. 41%, which was not statistically significant. However, those with no pulmonary manifestations and AKI were more likely to recover renal function, 100% vs. 29%, p =0.001. Table 5 outlines changes to participants' baseline immunosuppression regimen during COVID-19 illness, classified by presence or absence of pulmonary manifestations.

Immunosuppression changes classified by donor type can be seen in Table 6 . Two level comparisons based on (1) no change to regimen vs. (2) dose decreased or medication discontinued can be seen in Table 6a Of those on an antimetabolite-containing regimen, 87.5% had the antimetabolite either discontinued or the dose decreased during COVID-19 illness. Of those on a regimen with a CNI at baseline, 60% of participants had this discontinued or the dose decreased. Seventy-five percent of patients on maintenance glucocorticoids had these continued and 19.6% had these discontinued or the dose decreased ( Table 5) . Those with pulmonary manifestations were more likely than those without to have baseline CNI, antimetabolite, or prednisone dose either discontinued or decreased.

CNI were continued at the same dose vs. in those where the CNI was stopped or the dose was decreased. Patients who stopped CNI drugs showed significantly higher peak hsCRP than those who were maintained on the baseline dose, median (IQR) 344 (145-374) mg/L vs. 41 (22-116) mg/dL, p =0.032 (Figure 1b) . Initial ferritin levels were also found to be higher in those who had CNI drug decreased or discontinued as compared to those maintained on the same dose, median (IQR) 1271 (839-1932) ng/mL vs. 283 (124-569) ng/mL, p =0.0002 (Figure 1c) .

There was also a significantly higher peak WBC in those patients who had their CNI discontinued vs. maintained at the same dose, median (IQR) 19. XK/uL) vs. 6.3 XK/uL (4.7 XK/uL -8.2 XK/uL), p =0.002 (Figure 1f ). The results of the sensitivity analysis performed on only those patients who had CNI dosage adjusted prior to obtaining inflammatory biomarkers are depicted in Figure 2 . Of those patients whose CNI regimen was altered prior to biomarkers being obtained, the peak CRP was significantly higher if CNI was No significant differences in hs-CRP, ferritin, or WBC were found between patients whose anti-metabolite medications were maintained vs. discontinued or the dose changes during COVID-19 illness (Figure 3) . These results were confirmed in a sensitivity analysis using only those patients whose regimen was changed prior to biomarkers being obtained (data not shown). When the delta initial-to-peak change (peak minus initial value) in levels of hs-CRP, WBC, and ferritin were compared by regimen change, there was a statistically significant delta increase from initial to peak values in CRP and WBC in those who had CNI discontinued or dose changed (Figures 4a, 4e ). There were no significant initial-to-peak delta changes in levels of inflammatory markers between patients whose anti-metabolite drug was discontinued or decreased as compared to those maintained on the same dose (Figure 4b, 4d , 4f).

In participants with no evidence of pulmonary manifestations, no significant differences were found in hs-CRP, ferritin, or WBC based on changes to CNI regimen (Figure 5a , 5c, 5e).

In patients with presence of pulmonary manifestations, as compared to patients maintained on the same CNI dose, those who had CNI dose decreased or discontinued had significantly higher initial ferritin levels [median (IQR), 1347 (839-1963) ng/mL vs. 519 (303-585) ng/mL, p =0.005)]

and peak WBC [median (IQR), 13.3 XK/uL (6.6 X10/uL -23.3 XK/uL) vs. 7.5 XK/uL (4.4 XK/uL -8.2 XK/uL, p =0.04)] (Figure 5d , 5f).

Univariate analyses revealed that eGFR <60 mL/min/1.73 m 2 , peak hsCRP, final hsCRP, peak WBC, and decreased dose or discontinuation of CNI were significantly associated with the composite event (Table 7) . A multivariate backward variable selection model was constructed that included age, eGFR <60 mL/min/1.73 m 2 , peak hsCRP, peak WBC, and decreased or discontinued CNI. In this final model, factors associated with the composite event included eGFR <60 mL/min/1.73 m 2 , with an adjusted odds ratio (95% CI) of 11.18 (1.58, 79) , and peak hsCRP, with an adjusted odds ratio (95% CI) of 1.01 (1.00, 1.02) per unit increase in hsCRP.

The area under the curve (AUC) of the model was 0.887. The critical value cutoff of hsCRP associated with an adverse event was 171mg/L with an AUC of 0.79, sensitivity 0.62, specificity 1.0, positive predictive value (PPV) 1.0, negative predictive value (NPV) 0.52, positive likelihood ratio (PLR) ∞, negative likelihood ratio (NLR) 0.39 (p-value 0.02). The interaction of CNI (no change vs. decreased or discontinued) X pulmonary manifestations (present vs. absent) was not statistically significant in the multivariable logistic regression model for the composite outcome (p =0.92 for interaction term).

In this analysis, we observed that mortality among kidney transplant recipients with COVID-19 was 20% and that the majority of infected patients required hospitalization, while 22% required admission to the ICU, with 22% requiring mechanical ventilation. More than half (56%) developed an AKI, while about 17% developed an AKI requiring RRT. All with AKI but without pulmonary manifestations recovered renal function to 10% of their baseline at follow-up.

Importantly, a baseline eGFR <60 mL/min/1.73 m 2 and peak hsCRP during hospitalization were independently associated with worse outcomes. To our knowledge, we are the first to show a possible association between reduction or discontinuation of baseline CNI regimen and increase in inflammatory biomarkers. Patients with pulmonary manifestations of COVID-19 had a greater increase in their inflammatory biomarkers and were more likely to have their immunosuppression regimen changed compared to those without.

The mortality rate of 1 in 5 kidney transplant recipients infected with COVID-19 falls in a similar range as that reported by other United States (U.S.) transplant centers. Earlier reports, with small number of patients, showed extremely variable mortality rates, ranging from 0-60% 2-4, 7, 9, 16, 17 .Larger studies have showed similar mortality rates to our findings. Azzi et al found a death rate of 20.5% in all-comers and 37.8% in those transplant patients who required hospital admission 6 . Two large European studies showed 28-day mortality rates of 19.9% and 22.8% respectively 5, 18 . Many initial studies did not comment on AKI rates among transplant patients, and the rates of AKI requiring RRT are reported in only a handful of studies, with larger cohorts reporting rates lower than ours 5, 6 . Given that AKI is an important prognosticator in transplant recipients, we included it as part of the composite outcome. The rate of AKI in our cohort appears higher than initial reports involving smaller groups of transplant patients; these earlier findings described varying rates of AKI from 20-50% 4, 9, 16, 17 . This may be due to different ways of defining AKI. Our definition was robust in that we used the KDIGO guideline standard. Half of our cohort had eGFR <60 ml/min at presentation; underlying CKD, especially in a hospitalized setting, is a well-recognized AKI risk factor 19 .

There are as of yet no standardized guidelines for the management of immunosuppression in kidney transplant recipients with COVID-19 but most groups recommend reducing or stopping the antimetabolite in hospitalized patients 5, 16, 20 . Two other studies have evaluated changes in immunosuppression regimen and also assessed association of hs-CRP with COVID-19 disease severity, but none have investigated whether immunosuppression changes were associated with changes in hs-CRP or other inflammatory biomarkers 5, 6 . Few studies with larger samples lacked granular data to make such comparisons 18 or used only univariate models 6 . By comparing changes in inflammatory markers as they correlate with CNI dosing changes, we observed patients, with discontinued or decreased CNI dosing, having higher levels of inflammatory markers when compared to those individuals that had their baseline CNI dose continued. Interestingly, we found no changes to inflammatory markers with reduction or discontinuation of anti-metabolites, perhaps suggesting a stronger association of CNI reduction to COVID cytokine milieu. However, nearly 85% of our cohort had their antimetabolite reduced or stopped irrespective of the severity of illness, conceivably masking any impact of reduction on inflammatory markers. Those patients with pulmonary manifestations of COVID were more likely to have higher levels of inflammatory markers and to have their baseline CNI decreased or discontinued. This may be an indication bias, such that providers were more likely to decrease the dose or discontinue immunosuppressant medications in sicker patients. However, our sensitivity analysis including only patients in whom the change in immunosuppressive medications took place before inflammatory markers were measured suggests that indication bias may not account for the entire relationship.

We showed that CNI dose reduction or discontinuation, when compared to its dose maintenance, was associated with an increase in hs-CRP, ferritin, and WBC, and that hs-CRP was independently associated with worse outcomes. These findings are hypothesis generating and need confirmation in larger studies; a potential explanation could be that continuation of CNI ameliorated the COVID-induced host inflammatory response, manifested as a cytokine storm that may play an important role in the pathophysiology of multi-organ failure. Progression of COVID-19 lung infection has been described in distinct phases. The initial phase comprises of increasing COVID-19 disease severity, subsequently followed by a decline in viral response, and lastly, an enhanced host inflammatory response. In this final phase, seemingly uninhibited, systemic microvascular inflammation via production of multiple cytokines and inflammatory biomarkers such as hs-CRP can lead to multi-organ failure, including AKI 11, 20 . Remy et al proposed that COVID-19 viral injury occurs because of an impaired immune system response secondary to an immunocompromised state. Elevation of certain inflammatory markers has thereby been thought to be due to cellular injury of pulmonary epithelial cells 21 . Alternatively, the majority of groups have concluded that immunosuppression curbs the profound cytokine surge of COVID-19 10, 21, 22 . Other supporting evidence includes in-vitro data suggesting that CNIs at low levels inhibit growth of other coronaviruses; genome analysis show cyclophilin proteins and tacrolimus binding proteins interacting with SARS-CoV proteins with knock-out of the latter in tacrolimus treated patients inhibiting the virus replication 23-25 . Our findings suggest a potential role for continuation of at least low dose CNI in kidney transplant recipient in whom the cytokine surge seemingly predicts a worse outcome. We showed that CNI reduction or discontinuation was associated with increase in hs-CRP, ferritin, and WBC when compared to no change in CNI, and that hs-CRP was independently associated with worse outcomes. These findings, however, are hypothesis-generating and need to be confirmed in larger, prospective studies.

Several limitations are worth mentioning. Although we obtained granular data to ascertain associations between immunosuppression changes and inflammatory biomarkers, there is risk for indication bias as sicker patients with higher levels of inflammatory biomarkers at presentation would have had a higher probability to trigger reduction or discontinuation of immunosuppression. A larger sample size would have allowed propensity score analysis in order to match baseline characteristics of the patients, such as comorbid conditions and markers of illness, to further reduce potential indication bias. Another limitation is inter-hospital variability in clinical practice patterns as well as rapidly evolving knowledge of COVID-19 in transplant recipients. We were not able to determine whether changes in immunosuppression were driven by severity of COVID-19 illness, drug toxicity or targeting specific CNI troughs.

Future studies controlling for these factors are needed to guide changes in immunosuppression in the setting of COVID-19 infection.

In conclusion, kidney transplant patients infected with SARS-CoV-2 have high rates of ICU admissions, AKI, and death. Pulmonary manifestations and reduction or discontinuation in CNI regimen are associated with higher levels of inflammatory biomarkers that seem to correlate with worse outcomes. More studies are needed to determine if this association should drive clinical management in not only kidney transplant recipients but also that of other solid organs. Peak hs-CRP was higher in patients whose CNI was reduced or discontinued, and this change persisted in those whose regimen was changed prior to the laboratory results; this strengthens the use of hs-CRP as an important prognostic marker in renal transplant patients infected with SARS-CoV-2. Moreover, our findings may have potential therapeutic implications as ongoing studies look at immunomodulatory agents for potential treatments in COVID-19 disease.

The authors of this manuscript have no conflicts of interest to disclose. 

Estimated GFR, median (IQR), mL/min/1. Of the 59 total patients, 7 did not have serum creatinine values, so AKI could not be ascertained. Two patients had an AKI POA which recovered and subsequently developed another AKI while admitted, one patient had an AKI but was not admitted to the hospital. Experienced AKI, admitted to ICU, or died. 

Azathioprine No change 1/6 (16.7) 0/1 (0) 1/5 (20) 1 Dose increased 0/6 (0) 0/1 (0) 0/5 (0) Associations of inflammatory biomarkers and changes in CNI regimen. a) Initial, peak, and final hsCRP level in unchanged CNI compared to CNI decreased or discontinued. b) Initial, peak, and final hsCRP in unchanged CNI compared to both CNI decreased and CNI Figure 2 . Sensitivity analysis using only patients whose CNI was changed prior to biomarker laboratory results compared to patients with no changes in their CNI dosing. a) Initial, peak, and final hsCRP level in unchanged CNI compared to CNI decreased or discontinued. b) Initial, peak, and final hsCRP in unchanged CNI compared to both CNI decreased and CNI . Comparisons of delta change (peak value minus initial value) of inflammatory biomarkers and changes in immunosuppression regimen. a) Delta change of hsCRP for patients with unchanged CNI and those whose CNI was decreased or discontinued. b) Delta change of hsCRP for patients with unchanged anti-metabolite and those whose anti-metabolite was decreased or discontinued. c) Delta change of ferritin for patients with unchanged CNI and those whose CNI was decreased or discontinued. d) Delta change of ferritin for patients with unchanged anti-metabolite and those whose anti-metabolite was decreased or discontinued. e) Delta change of WBC for patients with unchanged CNI and those whose CNI was decreased or discontinued. f) Delta change of ferritin for patients with unchanged anti-metabolite and those whose anti-metabolite was decreased or discontinued. Significant P-values <0.05 are indicated on the corresponding figure. Each line represents one individual. Delta change of ferritin unable to be determined in any patients with no change to CNI due no available values in these patients.

Associations of inflammatory biomarkers and change in CNI regimen in patients with absence of pulmonary manifestations and those with the presence of pulmonary manifestations. a) Initial, peak, and final hsCRP level in unchanged CNI compared to CNI decreased or discontinued in those with no pulmonary manifestations. b) Initial, peak, and final hsCRP level in unchanged CNI compared to CNI decreased or discontinued in those with pulmonary manifestations. c) Initial ferritin level in unchanged CNI compared to CNI decreased or discontinued in those with no pulmonary manifestations. Peak and final ferritin levels unable to be compared due to small number of available values in both groups. d) Initial ferritin level in unchanged CNI compared to CNI decreased or discontinued in those with pulmonary manifestations. Peak and final ferritin levels unable to be compared due to small number of available values in no change group. e) Initial and peak WBC in unchanged CNI compared to CNI decreased or discontinued in those with no pulmonary manifestations. f) Initial and peak WBC in unchanged CNI compared to CNI decreased or discontinued in those with pulmonary manifestations. * represent significant p values <0.05.

Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a

MTOR-I, mammalian target of rapamycin inhibitor; prednisone refers to oral prednisone. Antimetabolite includes mycophenolate mofetil, azathioprine, and leflunomide

Antimetabolite includes mycophenolate mofetil, azathioprine, and leflunomide. discontinued. c) Initial ferritin level in unchanged CNI compared to CNI decreased or discontinued. d) Initial ferritin in unchanged CNI compared to both CNI decreased and CNI discontinued. Comparisons between peak and final ferritin unable to be made due to small number of available values in no change group. e) Initial and peak WBC in unchanged CNI compared to CNI decreased or discontinued. f) Initial and peak WBC in unchanged CNI compared to both CNI decreased and CNI discontinued. * represent significant p values <0.05. discontinued. c) Initial ferritin level in unchanged CNI compared to CNI decreased or discontinued. d) Initial ferritin in unchanged CNI compared to both CNI decreased and CNI discontinued. Comparisons between peak and final ferritin unable to be made due to small number of available values in no change group. e) Initial and peak WBC in unchanged CNI compared to CNI decreased or discontinued. f) Initial and peak WBC in unchanged CNI compared to both CNI decreased and CNI discontinued. * represent significant p values <0.05. compared to both anti-metabolite decreased and anti-metabolite discontinued. c) Initial, peak, and final ferritin level in unchanged anti-metabolite compared to anti-metabolite decreased or discontinued. d) Initial, peak, and final ferritin in unchanged anti-metabolite compared to both anti-metabolite decreased and antimetabolite discontinued. e) Initial and peak WBC in unchanged anti-metabolite compared to anti-metabolite decreased or discontinued. f) Initial and peak WBC